Results 91 to 100 of about 172,598 (105)
OBJECTIVES: We report a case of discordant total and free testosterone values in a patient with hypogonadism and juvenile hypophosphatasia after he initiated treatment with asfotase alfa, recombinant tissue non-specific alkaline phosphatase.
Eric T Rush, Whitney S Goldner
exaly +2 more sources
Interference of Asfotase Alfa in Immunoassays Employing Alkaline Phosphatase Technology [PDF]
BACKGROUND: Asfotase alfa (STRENSIQ®, Alexion Pharmaceuticals, Inc.) is the only approved treatment for patients with pediatric-onset hypophosphatasia, a disease caused by a mutation in the tissue-nonspecific alkaline phosphatase (TNSALP) gene.
Tompkins, Beatrice +2 more
exaly +2 more sources
Monitoring Guidance for Patients With Hypophosphatasia Treated With Asfotase Alfa [PDF]
Hypophosphatasia (HPP) is a rare, inherited, systemic, metabolic disorder caused by autosomal recessive mutations or a single dominant-negative mutation in the gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). The disease is associated with
Paul Harmatz +2 more
exaly +2 more sources
Asfotase Alfa for Infants and Young Children With Hypophosphatasia: 7 Year Outcomes of a Single-Arm, Open-Label, Phase 2 Extension Trial [PDF]
BACKGROUND: Our previous phase 2, open-label study of 11 infants and young children with life-threatening perinatal or infantile hypophosphatasia showed 1 year safety and efficacy of asfotase alfa, an enzyme replacement therapy.
Nicholas Bishop +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Status Epilepticus Due to Asfotase Alfa Interruption in Perinatal Severe Hypophosphatasia
Pediatric Neurology, 2022Hiroshi Yoshihashi +2 more
exaly
Dental Outcomes for Children Receiving Asfotase Alfa for Hypophosphatasia
Bone, 2021Cheryl Rockman-Greenberg +2 more
exaly
Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Journal of Clinical Endocrinology and Metabolism, 2016Nicholas Bishop +2 more
exaly

